DIVISLAB

Divi's Laboratories reiterated its commitment to achieving double-digit revenue growth and anticipates stable EBITDA margins despite facing competitive pricing pressures and increased raw material and freight costs. The company reported capital work in progress of ₹2,113 crores and FY26 Capex of ₹2,500 crores, with a steady capex plan for FY27 unless new major custom synthesis projects emerge. Growth is expected from healthy volume expansion in generics, a robust pipeline in custom synthesis with projects advancing towards commercialization, and significant investments in the peptide business, where the company aims for global leadership in scale. The management effectively mitigated supply chain and geopolitical disruptions, preventing any revenue loss in Q4 FY26.

Divi's Laboratories Limited reported consolidated financial results for the quarter ended March 31, 2026. Consolidated Revenue stood at ₹2,831 Cr vs ₹2,585 Cr (▲9.51% YoY). EBITDA was ₹1,089 Cr vs ₹972 Cr (▲11.93% YoY). PAT was ₹751 Cr vs ₹662 Cr (▲13.44% YoY). EBITDA Margin expanded from 37.60% to 38.47% (▲87bps). The company recommended a final dividend of ₹30/- per equity share for FY2025-26, and auditors issued an unmodified opinion.

Divi's Laboratories Limited announced the upload of the audio recording of its Q4 FY26 earnings conference call, held on May 23, 2026, for the quarter and year ended March 31, 2026, to the investors relations section of its website.

Consolidated Revenue for Q4 FY26 was ₹2,831Cr vs ₹2,585Cr (▲9.5% YoY), EBITDA was ₹934Cr vs ₹886Cr (▲5.4% YoY), and PAT was ₹751Cr vs ₹662Cr (▲13.4% YoY). EBITDA Margin was 33.0% vs 34.3% (▼128bps). The Board also recommended a final dividend of ₹30/- per equity share for FY 2025-26, and the 36th AGM is scheduled for August 10, 2026.

Divi's Laboratories Limited announced its Consolidated Financial Results for Q4 FY26. Consolidated Revenue stood at ₹2,831Cr against ₹2,585Cr (▲9.52% YoY), EBITDA at ₹934Cr against ₹886Cr (▲5.42% YoY), and PAT at ₹751Cr against ₹662Cr (▲13.44% YoY). The EBITDA Margin was 33.0% compared to 34.3% in the prior year quarter (▼130bps). The company also recommended a final dividend of ₹30 per equity share for FY2025-26.

Divi's Laboratories reported Consolidated Revenue of ₹2,831Cr vs ₹2,585Cr (▲9.5% YoY), EBITDA of ₹934Cr vs ₹886Cr (▲5.4% YoY), and PAT of ₹751Cr vs ₹662Cr (▲13.4% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 33.0% vs 34.3% (▼130bps). The Board also recommended a final dividend of ₹30/- per equity share for the financial year 2025-26.

Divi's Laboratories Limited announced an earnings conference call to discuss its audited financial results for the quarter and year ended March 31, 2026 (Q4FY26). The conference call is scheduled for May 23, 2026, at 14:30 hrs (IST).

Divi's Laboratories Limited submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026, confirming compliance regarding dematerialization of securities.

Divi's Laboratories Limited announced the closure of its trading window from April 01, 2026, until 48 hours after the declaration of audited financial results for the quarter and financial year ended March 31, 2026. The date of the Board meeting for results declaration will be intimated in due course.

Divi's Laboratories received a Draft Assessment Order for FY2022-23 proposing additions/disallowances of Rs.570.51 crores due to Transfer Pricing and corporate tax adjustments. This implies additional income tax liability and potential penalties for under-reporting. The company plans to appeal.

Transcript of Divi's Laboratories Limited's Q3FY2026 earnings conference call held on Feb 11, 2026. Highlights included stable Generics performance, progressing Custom Synthesis projects, healthy Nutraceuticals segment, a successfully concluded U.S. FDA inspection, and a one-time ₹74 Cr impact from new labor codes on employee benefits.

Divi's Laboratories Limited informed that the audio recording of the Q3FY26 earnings conference call, held on February 11, 2026, for the quarter and nine months ended December 31, 2025, has been uploaded to their website for investor access.

Consolidated Revenue ₹2,604Cr vs ₹2,319Cr (▲12.29% YoY), EBITDA ₹890Cr vs ₹743Cr (▲19.78% YoY), PAT ₹583Cr vs ₹589Cr (▼1.02% YoY). EBITDA Margin 34.18% vs 32.04% (▲214bps). The PAT decline is attributed to a one-time exceptional item of ₹74Cr for labour codes impact.

Divi's Laboratories Limited announced an earnings conference call on February 11, 2026, at 15:00 hrs (IST) to discuss the unaudited financial results for the quarter and nine months ended December 31, 2025 (Q3FY26).